was no compelling evidence of effect other than placebo and recommended that the Medicines and Healthcare products Regulatory Agency (MHRA) should not allow homeopathic product labels to make medical claims, that homeopathic products should no longer be licensed by the MHRA, as they are not medicines, and that further clinical trials of homeopathy could not be justified. They recommended that funding of homeopathic hospitals should not continue, and NHS doctors should not refer patients to homeopaths. By February 2011 only one-third of primary care trusts still funded homeopathy and by 2012 no British universities offered homeopathy courses. In July 2017, as part of a plan to save £200m a year by preventing the "misuse of scarce" funding, the NHS announced that it would no longer provide homeopathic medicines. A legal appeal by the British Homeopathic Association against the decision was rejected in June 2018. The Australian National Health and Medical Research Council completed a comprehensive review of the effectiveness of homeopathic preparations in 2015, in which it concluded that "there were no health conditions for which there was reliable evidence that homeopathy was effective. No good-quality, well-designed studies with enough participants for a meaningful result reported either that homeopathy caused greater health improvements than placebo, or caused health improvements equal to those of another treatment." On September 20, 2017, the European Academies' Science Advisory Council (EASAC) published its official analysis and conclusion on the use of homeopathic products, finding a lack of evidence that homeopathic products are effective, and raising concerns about quality control. Publication bias and other methodological problems The fact that individual randomized controlled trials have given positive results is not in contradiction with an overall lack of statistical evidence of efficacy. A small proportion of randomized controlled trials inevitably provide false-positive outcomes due to the play of chance: a statistically significant positive outcome is commonly adjudicated when the probability of it being due to chance rather than a real effect is no more than 5%―a level at which about 1 in 20 tests can be expected to show a positive result in the absence of any therapeutic effect. Furthermore, trials of low methodological quality (i.e. ones that have been inappropriately designed, conducted or reported) are prone to give misleading results. In a systematic review of the methodological quality of randomized trials in three branches of alternative medicine, Linde et al. highlighted major weaknesses in the homeopathy sector,